Myriad Genetics, Inc. is headquartered in Salt Lake City, UT. The company is focused on developing, producing and distributing genetic tests utilized in the oncology and women's and ...

Michael Ryskin, an analyst from Bank of America Securities, maintained the Sell rating on Myriad Genetics (MYGN – Research Report). The associated price target remains the same with $13.00.

SAN FRANCISCO — At the JP Morgan Healthcare Conference here on Wednesday, Myriad Genetics CEO Paul Diaz provided preliminary Q4 and full-year 2024 financial results, as well as full-year 2025 guidance ...

Myriad Genetics, Inc. announced its preliminary financial results for the fourth quarter and full year of 2024, projecting total revenues of $209 million to $211 million for Q4 and $836 million to ...

SALT LAKE CITY, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced select unaudited preliminary results for ...

(RTTNews) - Myriad Genetics (MYGN) reported preliminary results for the fourth quarter and full year ended December 31, 2024, and provided full year 2025 financial guidance. Fourth quarter GAAP ...

These preliminary results will be included in a presentation that will be made available through a live webcast in the investor relations section of the Myriad Genetics website at investor.myriad ...

These preliminary results will be included in a presentation that will be made available through a live webcast in the investor relations section of the Myriad Genetics website at investor.myriad.com ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...